Is Dr. Agarwals Health Care a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr. Agarwals Health Care Ltd is a average quality company .

Is Dr. Agarwals Health Care undervalued or overvalued?

The key valuation ratios of Dr. Agarwals Health Care Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Dr. Agarwals Health Care share price return in the past 10 years?

Data is not available for this company

Is Dr. Agarwals Health Care a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Dr. Agarwals Health Care Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Dr. Agarwals Health Care?

The latest standalone P/E ratio of Dr. Agarwals Health Care as of 25-Apr-2025 is 512.72.

What is the P/B ratio of Dr. Agarwals Health Care?

The latest standalone P/B ratio of Dr. Agarwals Health Care as of 25-Apr-2025 is 2.70.

Dr. Agarwals Health Care Ltd - Stock Valuation and Financial Performance

Name: Dr. Agarwals Health Care
Brand: Dr. Agarwals Health Care

BSE: 544350 | NSE: AGARWALEYE | Hospital & Healthcare Services |

Place order

Dr. Agarwals Health Share Price

₹386.60 -3.15 -0.81%
as on 25-Apr'25 16:59

DeciZen - make an informed investing decision on Dr. Agarwals Health

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Dr. Agarwals Health Care stock performance -

PE Chart Key Ratios

P/E Ratio (CD):

147.10

Market Cap:

12,218.1 Cr.

52-wk low:

370.1

52-wk high:

463.9

Is Dr. Agarwals Health Care Ltd an attractive stock to invest in?

10 Year X-Ray of Dr. Agarwals Health: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0%	0%	0%	0%	0%	10.5%	-1.1%	24.3%	21.5%	17.8%	-
Value Creation Index ⓘ	NA	NA	NA	NA	NA	-0.2	-1.1	0.8	0.6	0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	0	0	531	471	696	1,018	1,332	1,332
Sales YoY Gr.	-	NA	NA	NA	NA	NA	-11.2%	47.7%	46.2%	30.9%	-
Adj EPS ⓘ	0	0	0	0	0	-1.2	-2.8	1.6	3.9	2.3	2.6
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	148.7%	-41.2%	-
BVPS (₹) ⓘ	0	0	0	0	0	12.1	9	10.3	26.4	47.6	147.6
Adj Net Profit ⓘ	0	0	0	0	0	-23.6	-57.6	32.1	92.2	63.9	83
Cash Flow from Ops. ⓘ	0	0	0	0	0	103	99.2	164	233	346	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	1.6	1.9	1.8	1.5	1.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	NA	41.4%	30.9%
Adj EPS ⓘ	NA	NA	NA	-41.2%
BVPSⓘ	NA	NA	74.6%	80.5%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	-9.5	-26.6	16.2	21.9	6.5	2.7
Op. Profit Mgn % ⓘ	23.3	16.6	26.1	26.7	27.2	26.7
Net Profit Mgn % ⓘ	-4.3	-12.8	5.4	10	5.7	6.2
Debt to Equity ⓘ	0.7	1	1.4	0.6	0.3	-
Working Cap Days ⓘ	0	100	76	65	62	0
Cash Conv. Cycle ⓘ	0	1	-16	-12	-9	0

Recent Performance Summary

Latest Financials - Dr. Agarwals Health Care Ltd.

	Standalone	Consolidated
TTM EPS (₹)	0.8	2.6
TTM Sales (₹ Cr.)	835	1,332
BVPS (₹.) ⓘ	143.4	147.6
Reserves (₹ Cr.) ⓘ	4,499	4,632
P/BV ⓘ	2.70	2.62
PE ⓘ	512.72	147.10

From the Market
52 Week Low / High (₹)	370.10 / 463.85
All Time Low / High (₹)	370.10 / 463.85
Market Cap (₹ Cr.)	12,218
Equity (₹ Cr.)	31.6
Face Value (₹)	1
Industry PE ⓘ	42.2

Quarterly Results

Standalone Basis

Consolidated Basis

	Mar'24	YoY Gr. Rt. %	Jun'24	YoY Gr. Rt. %	Sep'24	YoY Gr. Rt. %	Dec'24	YoY Gr. Rt. %
Sales (₹ Cr.)ⓘ	317	-2.8	293	-3.9	312	-2.6	296	-4.9
Adj EPS (₹) ⓘ	8.2	-17.9	5.8	-31.2	6.5	-30.1	5	-40.4
Op. Profit Mgn % ⓘ	14.14	-245 bps	11.17	-404 bps	11.80	-397 bps	9.75	-486 bps
Net Profit Mgn % ⓘ	9.96	-183 bps	7.61	-299 bps	8.00	-312 bps	6.47	-385 bps

Management X-Ray of Dr. Agarwals Health:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Dr. Agarwals Health

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

No data found!

Key Ratios of Dr. Agarwals Health

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Peer Comparison

Company Name	CMP(₹)	Change ₹(%)	Market Cap	Net Sales (₹ Cr.)	Latest EPS (₹)	Net Profit Margin %	Latest P/E	Latest P/BV
Apollo Hospital Ent.	6,951.9	-209.2 (-2.9%)	Mid Cap	7,274	83.6	13.9	85.7	12.1
Max Healthcare Inst	1,068	-39.6 (-3.6%)	Mid Cap	5,406	10.4	19.5	106.8	11.9
Narayana Hrudayalay	1,787.4	-9.5 (-0.5%)	Small Cap	5,018	38.4	15.7	46.9	10.8
Aster DM Healthcare	505.3	-5.1 (-1%)	Small Cap	3,699	105.6	5.5	4.8	7.3
Global Health	1,214.8	-27.7 (-2.2%)	Mid Cap	2,280	14.6	15.8	85.1	10.6
Dr. Lal Pathlabs	2,906.6	118.9 (4.3%)	Small Cap	1,967	55.3	19.5	50.4	10.7
Dr. Agarwals Health	386.6	-3.2 (-0.8%)	-	1,332	2.6	5.7	148.3	2.6
Indraprastha Medical	402.9	-17.2 (-4.1%)	Small Cap	1,245	16.5	10	25.5	6.9
RainbowChildrenS Med	1,395.3	-30.3 (-2.1%)	Small Cap	1,237	23	17.4	62	10.1
Krishna Inst.Medi	674.1	7 (1%)	Small Cap	1,222	6.4	19.3	103.6	12.9

Shows rows:

Prev 1 2 3 4 5 Next

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	531	471	696	1,018	1,332
Operating Expenses ⓘ	407	394	514	748	970
Manufacturing Costs	153	142	184	290	397
Material Costs	69	60	84	113	137
Employee Cost	112	116	140	190	243
Other Costs ⓘ	74	77	107	155	194
Operating Profit ⓘ	124	77	182	270	362
Operating Profit Margin (%)	23.3%	16.3%	26.1%	26.5%	27.2%
Other Income ⓘ	13	14	22	18	49
Interest ⓘ	54	44	49	76	101
Depreciation ⓘ	93	95	98	128	170
Exceptional Items ⓘ	0	0	0	0	0
Profit Before Tax ⓘ	-11	-48	57	84	141
Tax ⓘ	9	10	14	-20	46
Profit After Tax	-20	-58	43	103	95
PAT Margin (%)	-3.7%	-12.4%	6.2%	10.1%	7.1%
Adjusted EPS (₹)	-1.0	-2.7	1.8	4.0	3.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	249	184	212	628	1,333
Share Capital ⓘ	7	7	7	8	9
Reserves ⓘ	242	177	206	620	1,324
Minority Interest	18	14	21	30	40
Debt	157	178	264	310	325
Long Term Debt	145	168	254	306	310
Short Term Debt	12	10	10	5	15
Trade Payables	64	75	89	101	133
Others Liabilities ⓘ	252	323	425	701	885
Total Liabilities ⓘ	740	774	1,012	1,770	2,716
Fixed Assets
Gross Block	738	854	1,082	1,794	2,399
Accumulated Depreciation	188	279	381	501	653
Net Fixed Assetsⓘ	551	575	701	1,293	1,746
CWIP ⓘ	8	11	28	99	118
Investmentsⓘ	1	0	0	34	471
Inventories	33	28	33	36	52
Trade Receivables	52	47	57	76	97
Cash Equivalents	44	65	117	149	125
Others Assetsⓘ	50	48	76	83	108
Total Assets ⓘ	740	774	1,012	1,770	2,716

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	103	99	164	233	346
PBT ⓘ	-11	-48	57	84	141
Adjustment ⓘ	139	145	138	197	233
Changes in Working Capital ⓘ	-9	10	-15	-13	5
Tax Paid ⓘ	-16	-7	-16	-35	-32
Cash Flow From Investing Activity ⓘ	-80	-37	-155	-509	-914
Capex	-201	-33	-70	-157	-228
Net Investments	0	0	-87	-348	-684
Others ⓘ	122	-3	1	-4	-2
Cash Flow From Financing Activityⓘ	-73	-37	35	303	553
Net Proceeds from Shares ⓘ	0	0	0	301	640
Net Proceeds from Borrowing ⓘ	3	22	0	0	0
Interest Paid ⓘ	-32	-19	-21	-29	-32
Dividend Paid ⓘ	0	0	0	0	-1
Others ⓘ	-45	-40	56	32	-54
Net Cash Flow ⓘ	-50	25	44	27	-15

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	-7.89	-26.95	21.77	24.58	9.69
ROCE (%)	10.53	-1.09	24.26	21.51	17.77
Asset Turnover Ratio	0.72	0.62	0.78	0.73	0.59
PAT to CFO Conversion(x)	N/A	N/A	3.81	2.26	3.64
Working Capital Days
Receivable Days	36	38	27	24	24
Inventory Days	23	24	16	12	12
Payable Days	340	420	357	306	312

Dr. Agarwals Health Care Ltd Stock News

View All News

Dr. Agarwals Health Care Ltd FAQs

What is the share price of Dr. Agarwals Health?

Company share prices are keep on changing according to the market conditions. The closing price of Dr. Agarwals Health on 25-Apr-2025 16:59 is ₹386.6.

What is the market cap of Dr. Agarwals Health?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 25-Apr-2025 16:59 the market cap of Dr. Agarwals Health stood at ₹12,218.1.

What is the P/E ratio of Dr. Agarwals Health?

The latest P/E ratio of Dr. Agarwals Health as of 25-Apr-2025 16:59 is 512.7.

What is the P/B ratio of Dr. Agarwals Health?

The latest P/B ratio of Dr. Agarwals Health as of 25-Apr-2025 16:59 is 2.70.

What is the 52-week high and low of Dr. Agarwals Health?

The 52-week high of Dr. Agarwals Health is ₹463.9 and the 52-week low is ₹370.1.

What is the TTM revenue of Dr. Agarwals Health?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dr. Agarwals Health is ₹835.1 ( Cr.) .

About Dr. Agarwals Health Care Ltd

Dr. Agarwal's Health Care Limited was incorporated at Chennai, Tamil Nadu as a public limited company under the Companies Act, 1956, pursuant to the certificate of incorporation dated April 19, 2010, issued by the RoC and commenced operations pursuant to the certificate for commencement of business dated May 29, 2010, issued by the RoC.

Dr. Agarwal's Health Care provides a comprehensive range of eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lenses and accessories, and eye care related pharmaceutical products. The company had a market share of around 25% of the total eye care service chain market in India during the Financial Year 2024. The company categorizes its Facilities as Primary Facilities [which are non-surgical eye care facilities); Secondary Facilities (which are surgical Facilities); and Tertiary Facilities (which are super-specialty surgical Facilities and include three centres of excellence (COEs)], depending upon the nature of services provided. The company’s business operations are structured as a “hub and spoke” model, which enables it to build a scalable and accessible platform for the continued growth of its business.

The company’s Primary Facilities provide initial eye care diagnosis and clinical investigation services. The Secondary Facilities at its spokes provide select services including cataract surgeries and clinical investigations while its Tertiary Facilities have super-specialty surgical capabilities including retinal, corneal, and refractive surgeries. The company’s COEs, in addition to being Tertiary Facilities, also offer academic programs in ophthalmology and provide continuous training for its doctors, optometrists, and counsellors, among others. Its integrated hub and spoke model enable deeper geographic penetration, allowing greater accessibility to patients while driving efficiency of critical resources across the network.

Business area of the company

The company and its subsidiaries/associate are primarily engaged in running, owning and managing eye care hospitals, opticals, pharmacies, etc.

Awards and accreditation

2023: AHCL was awarded as ‘One of the Best Healthcare Brands - 2023’ at The Economic Times Best Healthcare Brands 2023.
2024: ‘Best Employer 2024-2025 - Tamil Nadu’ at the 19th Employer Branding Awards.
2022: AHCL was awarded ‘E4M Pride of India Brands’ at the Best of Bharat Awards 2022.
2022: AHCL was awarded the ‘Best Eye Hospital’ at the Pulse Healthcare Awards, Tamil Nadu.
2023: AHCL was ranked as ‘India’s Most Trusted Eye Hospitals category’ in the Trust Research Advisory’s Brand Trust Report, India Study 2023.
2024: AHCL was awarded the Bronze award for ‘Digital Initiative for Patient Education’ award at the Smart Hospitals and Diagnostic Awards, 2024.
2024: AHCL was awarded the ‘Best Use of TV in Healthcare - Gold’ and ‘Best Use of Print in Healthcare - Silver’ awards at the annual e4m Indian Marketing Awards, 2024 - South.

History and milestones

2010: Incorporation of the company.
2010: Entry into the Telangana (formerly a part of Andhra Pradesh) and Karnataka markets by entering into lease agreements for setting up eye clinics.
2011: Investment by EILSF SPV 3 in the company.
2012: Entry into the Africa market by entering into an agreement with Dr, Amelia Buque to jointly promote eye hospitals and other health care related services in Mozambique.
2017: Entry into the Maharashtra market through the acquisition of hospital facilities in Maharashtra.
2019: Investment by Claymore Investments (Mauritius), an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited and Value Growth Investment Holdings Pte. Ltd in the company through subscription of equity shares.
2019: Subscription of NCDs by British International Investment (formerly known as CDC Group PLC) in the company.
2021: The Company launched its 100th eye care facility.
2022: Investment by TPG Capital’s Hyperion Investments Pte. Ltd. and Arvon Investments Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited in the Company through subscription of equity shares.
2022: Entry into the Jammu market through the acquisition of Dr. Sood eye care practices from Dr. Rohan and Raj Deep Sood.
2022: Strengthened presence in the Gujarat market through acquisition of the eye care business from Prizma Eyecare LLP, Dr. Sanjay Vallabhai Savani and Dr. Ashish P. Gusani
2023: Strengthened presence in the Punjab market through the acquisition of Punjab Eye Hospital from Dr. Gurpal Singh.
2024: Entry in the Uttar Pradesh market through the acquisition of an eye care business in Varanasi. Expanded its` presence in Punjab market by acquisition of Dr Thind Eye Care Private Limited.